Cargando…

Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers

OBJECTIVES: Reimbursement decisions require evidence of effectiveness and, in general, a blinded randomised controlled trial (RCT) is the preferred study design to provide it. However, there are situations where a cohort study, or even patient series, can be deemed acceptable. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: de Groot, Saskia, Rijnsburger, Adriana J, Versteegh, Matthijs M, Heymans, Juanita M, Kleijnen, Sarah, Redekop, W Ken, Verstijnen, Ilse M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521513/
https://www.ncbi.nlm.nih.gov/pubmed/26220869
http://dx.doi.org/10.1136/bmjopen-2014-007241
_version_ 1782383824689168384
author de Groot, Saskia
Rijnsburger, Adriana J
Versteegh, Matthijs M
Heymans, Juanita M
Kleijnen, Sarah
Redekop, W Ken
Verstijnen, Ilse M
author_facet de Groot, Saskia
Rijnsburger, Adriana J
Versteegh, Matthijs M
Heymans, Juanita M
Kleijnen, Sarah
Redekop, W Ken
Verstijnen, Ilse M
author_sort de Groot, Saskia
collection PubMed
description OBJECTIVES: Reimbursement decisions require evidence of effectiveness and, in general, a blinded randomised controlled trial (RCT) is the preferred study design to provide it. However, there are situations where a cohort study, or even patient series, can be deemed acceptable. The aim of this study was to develop an instrument that first examines which study characteristics of a blinded RCT are necessary, and then, if particular characteristics are considered necessary, examines whether these characteristics are feasible. DESIGN: We retrospectively studied 22 interventions from 20 reimbursement reports concerning medical specialist care made by the Dutch National Health Care Institute (ZIN) to identify any factors that influenced the necessity and feasibility of blinded RCTs, and their constituent study characteristics, that is, blinding, randomisation and a control group. A literature review was performed to identify additional factors. Additional expertise was included by interviewing eight experts in epidemiology, medicine and ethics. The resulting instrument was called the FIT instrument (Feasible Information Trajectory), and was prospectively validated using three consecutive reimbursement reports. RESULTS: (Blinded) RCT evidence was lacking in 5 of 11 positive reimbursement decisions and 3 of 11 negative decisions. In the reimbursement reports, we found no empirical evidence supporting situations where a blinded RCT is unnecessary. The literature also revealed few arguments against the necessity of a blinded RCT. In contrast, many factors influencing the feasibility of randomisation, a control group and blinding, were found in the reimbursement reports and the literature; for example, when a patient population is too small or when an intervention is common practice, randomisation will be hindered. CONCLUSIONS: Policy regarding the necessity and feasibility of different types of evidence of effectiveness would benefit from systematic guidance. The FIT instrument has the potential to support transparent, reproducible and well-founded decisions on appropriate evidence of effectiveness in medical specialist care.
format Online
Article
Text
id pubmed-4521513
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-45215132015-08-05 Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers de Groot, Saskia Rijnsburger, Adriana J Versteegh, Matthijs M Heymans, Juanita M Kleijnen, Sarah Redekop, W Ken Verstijnen, Ilse M BMJ Open Health Policy OBJECTIVES: Reimbursement decisions require evidence of effectiveness and, in general, a blinded randomised controlled trial (RCT) is the preferred study design to provide it. However, there are situations where a cohort study, or even patient series, can be deemed acceptable. The aim of this study was to develop an instrument that first examines which study characteristics of a blinded RCT are necessary, and then, if particular characteristics are considered necessary, examines whether these characteristics are feasible. DESIGN: We retrospectively studied 22 interventions from 20 reimbursement reports concerning medical specialist care made by the Dutch National Health Care Institute (ZIN) to identify any factors that influenced the necessity and feasibility of blinded RCTs, and their constituent study characteristics, that is, blinding, randomisation and a control group. A literature review was performed to identify additional factors. Additional expertise was included by interviewing eight experts in epidemiology, medicine and ethics. The resulting instrument was called the FIT instrument (Feasible Information Trajectory), and was prospectively validated using three consecutive reimbursement reports. RESULTS: (Blinded) RCT evidence was lacking in 5 of 11 positive reimbursement decisions and 3 of 11 negative decisions. In the reimbursement reports, we found no empirical evidence supporting situations where a blinded RCT is unnecessary. The literature also revealed few arguments against the necessity of a blinded RCT. In contrast, many factors influencing the feasibility of randomisation, a control group and blinding, were found in the reimbursement reports and the literature; for example, when a patient population is too small or when an intervention is common practice, randomisation will be hindered. CONCLUSIONS: Policy regarding the necessity and feasibility of different types of evidence of effectiveness would benefit from systematic guidance. The FIT instrument has the potential to support transparent, reproducible and well-founded decisions on appropriate evidence of effectiveness in medical specialist care. BMJ Publishing Group 2015-07-28 /pmc/articles/PMC4521513/ /pubmed/26220869 http://dx.doi.org/10.1136/bmjopen-2014-007241 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Health Policy
de Groot, Saskia
Rijnsburger, Adriana J
Versteegh, Matthijs M
Heymans, Juanita M
Kleijnen, Sarah
Redekop, W Ken
Verstijnen, Ilse M
Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers
title Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers
title_full Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers
title_fullStr Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers
title_full_unstemmed Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers
title_short Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers
title_sort which factors may determine the necessary and feasible type of effectiveness evidence? a mixed methods approach to develop an instrument to help coverage decision-makers
topic Health Policy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521513/
https://www.ncbi.nlm.nih.gov/pubmed/26220869
http://dx.doi.org/10.1136/bmjopen-2014-007241
work_keys_str_mv AT degrootsaskia whichfactorsmaydeterminethenecessaryandfeasibletypeofeffectivenessevidenceamixedmethodsapproachtodevelopaninstrumenttohelpcoveragedecisionmakers
AT rijnsburgeradrianaj whichfactorsmaydeterminethenecessaryandfeasibletypeofeffectivenessevidenceamixedmethodsapproachtodevelopaninstrumenttohelpcoveragedecisionmakers
AT versteeghmatthijsm whichfactorsmaydeterminethenecessaryandfeasibletypeofeffectivenessevidenceamixedmethodsapproachtodevelopaninstrumenttohelpcoveragedecisionmakers
AT heymansjuanitam whichfactorsmaydeterminethenecessaryandfeasibletypeofeffectivenessevidenceamixedmethodsapproachtodevelopaninstrumenttohelpcoveragedecisionmakers
AT kleijnensarah whichfactorsmaydeterminethenecessaryandfeasibletypeofeffectivenessevidenceamixedmethodsapproachtodevelopaninstrumenttohelpcoveragedecisionmakers
AT redekopwken whichfactorsmaydeterminethenecessaryandfeasibletypeofeffectivenessevidenceamixedmethodsapproachtodevelopaninstrumenttohelpcoveragedecisionmakers
AT verstijnenilsem whichfactorsmaydeterminethenecessaryandfeasibletypeofeffectivenessevidenceamixedmethodsapproachtodevelopaninstrumenttohelpcoveragedecisionmakers